Merger with Private Molecular - Additional Information (Detail) - USD ($) |
3 Months Ended | ||||
|---|---|---|---|---|---|
Aug. 01, 2017 |
Mar. 31, 2018 |
Mar. 31, 2017 |
Jun. 01, 2017 |
Mar. 24, 2017 |
|
| Business Acquisition [Line Items] | |||||
| Exercise price per share on stock options after reverse stock split | $ 10.69 | ||||
| Stock compensation | $ 643,000 | $ 26,000 | |||
| 2014 Equity Incentive Plan | |||||
| Business Acquisition [Line Items] | |||||
| Stock compensation | $ 1,200,000 | ||||
| Threshold | |||||
| Business Acquisition [Line Items] | |||||
| Common stock shares issued in exchange of each share | 7.7844 | ||||
| Threshold equity holders ownership interest | 34.40% | ||||
| Private Molecular equity holders ownership interest | 65.60% | ||||
| Stock option outstanding to purchase common stock | 963,681 | ||||
| Number of vested stock option shares after reverse stock split | 963,681 | ||||
| Exercise price per share on stock options after reverse stock split | $ 33.62 | ||||
| Fair value inputs discount rate | 12.00% | ||||
| Transaction costs associated with Merger | $ 2,000,000 | ||||
| Principal amount | $ 2,000,000 | $ 2,000,000 | |||
| Promissory note interest rate | 1.00% | ||||
| X | ||||||||||
- Definition Molecular Templates equity holders ownership interest on a fully diluted basis upon consummation of the transaction. No definition available.
|
| X | ||||||||||
- Definition Exchange ratio of company common stock shares exchanged for each share owned by private molecular stockholders. No definition available.
|
| X | ||||||||||
- Definition Promissory note interest rate. No definition available.
|
| X | ||||||||||
- Definition Promissory Notes Receivable. No definition available.
|
| X | ||||||||||
- Definition Stock option outstanding to purchase common stock. No definition available.
|
| X | ||||||||||
- Definition Threshold equity holders ownership interest. No definition available.
|
| X | ||||||||||
- Definition Represents the expense recognized during the period arising from equity-based compensation arrangements (for example, shares of stock, unit, stock options or other equity instruments) with employees, directors and certain consultants qualifying for treatment as employees. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
- Definition Amount of direct costs of the business combination including legal, accounting, and other costs incurred to consummate the business acquisition. No definition available.
|
| X | ||||||||||
- Definition Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. No definition available.
|
| X | ||||||||||
- Definition Interest rate used to find the present value of an amount to be paid or received in the future as an input to measure fair value. For example, but not limited to, weighted average cost of capital (WACC), cost of capital, cost of equity and cost of debt. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
- Definition Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options. No definition available.
|
| X | ||||||||||
- Definition Number of options vested. No definition available.
|
| X | ||||||||||
- Details
|
| X | ||||||||||
- Details
|